Medindia LOGIN REGISTER
Medindia
Advertisement

AmniScreen(TM) Amniotic Fluid Detection Device is Now Available

Friday, February 22, 2008 General News
Advertisement
MONTVALE, N.J., Feb. 21 Barr Pharmaceuticals,Inc. (NYSE: BRL) today announced the launch of AmniScreen(TM), the first andonly FDA-approved at-home screening test for amniotic fluid leakage duringpregnancy. AmniScreen is a prescription-only panty liner device that includesa proprietary polymer-coated polyester strip designed to detect amniotic fluidleakage, which could indicate a potential problem with a pregnancy. Barr'sproprietary subsidiary, Duramed Pharmaceuticals, Inc., will detail AmniScreento physicians and healthcare providers with its Specialty and InstitutionalSales Forces.
Advertisement

"AmniScreen may offer reassurance to women concerned about unexplainedvaginal wetness during pregnancy. The product detects amniotic fluid leakagethat can lead to serious complications, such as infection and pretermlabor,(1)" says Nancy Jasper, MD, Assistant Clinical Professor, Department ofOb/Gyn, Columbia University, College of Physicians and Surgeons. "It'simportant for women to know when wetness may be caused by amniotic fluidleakage."
Advertisement

In July 2006, Barr announced that it had entered into a development,manufacturing and supply agreement with Common Sense Ltd. for AmniScreen.Under the terms of the agreement, the Company agreed to make a one-timepayment to Common Sense following FDA approval.

Common Sense will manufacture and package the product and Duramed willdetail to physicians and healthcare providers. Barr will record net sales ofthe product and will pay Common Sense for product delivered.

How AmniScreen Works

AmniScreen works by detecting elevated pH levels, which may indicateamniotic fluid leakage.(2) Patients are instructed to report or show testresults to their healthcare provider for interpretation and medical care.(3)The pivotal trial demonstrated that AmniScreen detected amniotic fluid leakageabout 96% of the time.(4) During the trial, patient-read results andclinician-read results matched more than 97% of the time.(5)

Potential Candidates

Pregnant women who experience unexplained vaginal wetness are potentialcandidates for AmniScreen. Additional candidates include high-risk pregnantwomen, women who have undergone amniocentesis, have experienced prior amnioticleakage, and those who are concerned about unexplained wetness.

Safety Information

The AmniScreen Home Detection Liner Kit is intended to detect possibleleakage of amniotic fluid when vaginal wetness is experienced during pregnancyby indicating pH level. pH levels greater than or equal to 5.2 produce ablue-green color. Patients are instructed to report or show test results totheir healthcare provider for interpretation and medical care.

AmniScreen should not be used if less than 12 hours have passed sincesexual intercourse or vaginal douching. AmniScreen should not be used ifthere is vaginal bleeding or spotting. A healthcare provider should beconsulted if there is unexplained wetness, vaginal bleeding or spotting, orsuspicion of vaginal infection.

Marketing Agreement

Under a marketing agreement, Barr's proprietary subsidiary, DuramedPharmaceuticals, Inc., will launch AmniScreen immediately and will detail theproduct to physicians and healthcare providers with its Specialty andInstitutional Sales Forces. AmniScreen was developed by the privately-ownedcompany Common Sense, which was founded in 1999 and is a leading developer andmanufacturer of indicators utilizing common hygienic products such aspanty-liners and diapers as a platform for non-intrusive diagnosis and healthcondition monitoring.

About Barr Pharmaceuticals, Inc.

Barr Pharmaceuticals, Inc. is a global specialty pharmaceutical companythat operates in more than 30 countries worldwide and is engaged in thedevelopment, manufacture and marketing of generic and proprietarypharmaceuticals, biopharmaceuticals and active pharmaceutical i
Sponsored Post and Backlink Submission


Latest Press Release on General News

This site uses cookies to deliver our services.By using our site, you acknowledge that you have read and understand our Cookie Policy, Privacy Policy, and our Terms of Use  Ok, Got it. Close